Abstract
Objectives
Physiological changes occurring in patients with diabetes may affect the pharmacokinetics and penetration of antimicrobial agents into peripheral tissue. We examined the pharmacokinetics and the penetration of moxifloxacin into perinecrotic tissue of diabetic foot lesions in patients with diabetic foot infections (DFI).
Patients and methods
Adult patients suffering from type 2 diabetes mellitus and hospitalized for DFI (Texas classification of at least B2) were treated with 400 mg moxifloxacin intravenously (IV) or orally (PO) once daily. The pharmacokinetics of moxifloxacin and its concentration 3 h after administration in samples of perinecrotic tissue resected from infected diabetic foot wounds were determined at steady state (days 4–8).
Results
A total of 53 patients with diabetes mellitus type 2 (mean age 69.4 ± 10.8 years) were included in the study, of whom 28 received PO and 25 IV moxifloxacin therapy for a median of 8 days. In the PO and IV subgroups, the mean maximum observed plasma concentration (C max) in plasma was 2.69 and 4.77 mg/l at a median of 2 [time to reach C max (T max) range 1.0–8.0 h] and 1 h after administration, respectively. A mean area under the plasma concentration–time curve from time 0 until the last quantifiable plasma concentration (AUC0-24 h) of 29.36 mg h/l (PO) and 27.09 mg h/l (IV) was achieved. Mean moxifloxacin concentrations in perinecrotic tissue of infected diabetic foot wounds following PO or IV administration were 1.79 ± 0.82 and 2.20 ± 1.54 μg/g, thus exceeding the MIC90 (minimum inhibitory concentration required to inhibit growth of 90% of organisms) for Staphylococcus aureus (0.25 mg/l) by seven- and eightfold and the MIC90 for Escherichia coli (0.06 mg/l) by 29-fold and 36-fold, respectively. The mean tissue-to-plasma ratios of moxifloxacin concentration 3 h after administration were 1.01 ± 0.57 (PO) and 1.09 ± 0.69 (IV). Significant differences between the routes of administration were observed for T max and C max (P < 0.01), but not for other clinically relevant parameters (AUC0-24; moxifloxacin DFI tissue concentration).
Conclusions
The plasma concentration–time curve of moxifloxacin in diabetic patients is similar to that of healthy volunteers. We also observed a good penetration of moxifloxacin into inflamed DFI tissue which taken together with the possibility of sequential IV/PO therapy suggest that moxifloxacin 400 mg once daily is a therapeutic option in the treatment of DFI caused by susceptible organisms.
Similar content being viewed by others
References
Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS (2004) Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885–910. http://www.journals.uchicago.edu/doi/full/10.1086/424846
Lipsky BA, Giordano P, Choudhri S, Song J (2007) Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin–tazobactam/amoxicillin–clavulanate. J Antimicrob Chemother 60:370–376. http://jac.oxfordjournals.org/cgi/content/abstract/60/2/370?etoc
Stengel D, Graninger W (2005) Antimicrobial treatment of diabetic foot infections. Effects of primary and secondary prevention measures on amputation rates. Chemotherapie J 14:191–197. http://www.wissenschaftliche-verlagsgesellschaft.de/CTJ/CTJ2005/CTJ-6-05/stengel-1.pdf
Oberdorfer K, Swoboda S, Hamann A, Baertsch U, Kusterer K, Born B, Hoppe-Tichy T, Geiss HK, von Baum H (2004) Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother 54:836–839. http://jac.oxfordjournals.org/cgi/content/full/54/4/836
Majcher-Peszynska J, Haase G, Saß M, Mundkowski R, Pietsch A, Klammt S, Schareck W, Drewelow B (2008) Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 64:1093–1100. http://www.springerlink.com/content/703t7j5qr1w41165/
Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, Towne JB (2004) In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 48:1012–1016. http://aac.asm.org/cgi/content/full/48/3/1012?view=long&pmid=14982797
Joukhadar C, Stass H, Müller-Zellenberg U, Lackner E, Kovar F, Minar E, Müller M (2003) Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 47:3099–3103. http://aac.asm.org/cgi/content/full/47/10/3099?view=long&pmid=14506015
Wacke R, Förster S, Adam U, Mundkowski RG, Klar E, Hopt UT, Drewelow B (2006) Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 58:994–999. http://jac.oxfordjournals.org/cgi/content/full/58/5/994
Citron DM, Goldstein EJC, Merriam CV, Lipsky BA, Abramson MA (2007) Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 45:2819–2828. http://jcm.asm.org/cgi/content/full/45/9/2819?view=long&pmid=17609322
Edmiston CE, Krepel CJ, Kehl KS, Seabrook GR, Somberg LB, Almassi GH, Smith TL, Loehrl TA, Brown KR, Lewis BD, Towne JB (2005) Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J Antimicrob Chemother 56:872–878. http://jac.oxfordjournals.org/cgi/content/full/56/5/872
Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Reimnitz P, Bogner JR, The STIC Study Group (2009) Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection 37(5):407–417. http://www.springerlink.com/content/c622602821776232/
Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP (2008) In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 52(11):3941–3946. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2573116/pdf/0589-08.pdf
Stass H, Kubitza D (1999) Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 43:83–90. http://jac.oxfordjournals.org/cgi/reprint/43/suppl_2/83
Stass H, Dalhoff A (2005) The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Infection 33:29–35. http://www.springerlink.com/content/j651rt2833463465/
Burkhard O, Welte T (2009) 10 years' experience with the pneumococcal quinolone moxifloxacin. Expert Rev Anti Infect Ther 7(6):645–668. http://www.expert-reviews.com/doi/abs/10.1586/eri.09.46?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov
Gyssens IC, Dryden M, Kujath P, Nathwani D, Schaper N, Arvis P, Reimnitz P, Alder J, Hampel B. Efficacy of IV/oral moxifloxacin in the treatment of complicated skin and skin-structure infections: results of the RELIEF study. In: 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, P1785. http://www.blackwellpublishing.com/eccmid19/abstract.asp?id=75391
Wirtz M, Kleeff J, Swoboda S, Halaceli I, Geiss HK, Hoppe-Tichy T, Büchler MW, Friess H (2004) Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 53(5):875–877. http://jac.oxfordjournals.org/cgi/reprint/53/5/875
Soman A, Honeybourne D, Andrews J, Jevons G, Wise R (1999) Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 44(6):835–838. http://jac.oxfordjournals.org/cgi/reprint/44/6/835
Schaper N, Dryden M, Kujath P, Nathwani D, Arvis P, Reimnitz P, Alder J, Hampel B, Gyssens IC (2010) Efficacy of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanate in the treatment of diabetic foot infections: results of the RELIEF study. In: 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, P1550. http://www3.interscience.wiley.com/cgi-bin/fulltext/123359225/PDFSTART
Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones. Clin Pharmacokinet 41(10):741–750. http://www.ingentaconnect.com/content/adis/cpk/2002/00000041/00000010/art00004
Pascual A, García I, Ballesta S, Perea EJ (1999) Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob Agents Chemother 43(1):12–15. http://aac.asm.org/cgi/reprint/43/1/12
Acknowledgments
The authors express their thanks for the excellent technical assistance provided by Katrin Kroesche and Andrea Bruss. We thank Klaus A. Schmidt, Aachen, for his assistance in the preparation of the manuscript.
Funding
This study was supported in part by an unrestricted grant by Bayer Vital GmbH, Leverkusen, Germany.
Conflict of interest statement:
J.M.P. has received speaking fee from Bayer Vital GmbH.
M.S. has no conflict of interest.
S.S. has no conflict.
V.C. has received research support from Bayer Vital GmbH.
A.G. has received research support from Bayer Vital GmbH.
R.L. has received a speaking fee from Bayer Vital GmbH.
R.G.M.has received research grants from Bayer Vital GmbH.
C.L. has no conflict.
P.K. has received a speaking fee from Bayer Vital GmbH.
B.R. has received research grants from Bayer Vital GmbH.
H.H.K. has received a speaking fee from Bayer Vital GmbH.
W.S. has no conflict.
E.K. has received research grants from Bayer Vital GmbH.
B.D. has served as a consultant and received research grants from Bayer Vital GmbH.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The results of an interim analysis of this study were presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006; abstract P1516. Available at: http://www.blackwellpublishing.com/eccmid16/abstract.asp?id=50311
Rights and permissions
About this article
Cite this article
Majcher-Peszynska, J., Sass, M., Schipper, S. et al. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. Eur J Clin Pharmacol 67, 135–142 (2011). https://doi.org/10.1007/s00228-010-0903-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-010-0903-5